IDH1 and central nervous system cancer: The results showed that this classification had significantly different clinical patterns in WHO grade (p = 5.96e‐21), chemotherapy treatment status (p = 0.0102), radiotherapy treatment status (p = 0.0236), IDH mutation status (p = 1.387e‐15), age (p = 2.66e‐05), and primary or recurrent glioma (p = 6.19e‐10).